Investment Thesis
CNMD demonstrates solid operational cash generation (FCF margin 11%) and healthy liquidity (2.14x current ratio), but faces significant headwinds including flat revenue growth, sharp net income decline (-64.5% YoY), and weakening profitability margins (net margin 3.4%). The company's leverage remains manageable at 0.81x debt-to-equity, though deteriorating earnings quality requires monitoring of operational execution and market demand.
Strengths
- Strong free cash flow generation of $150.9M with 11% FCF margin indicates robust operational efficiency
- Solid liquidity position with 2.14x current ratio and quick ratio of 1.01x supports financial stability
- Healthy gross margin of 54.6% reflects underlying product competitiveness and pricing power in medical device market
- Moderate leverage at 0.81x debt-to-equity with 3.3x interest coverage provides financial flexibility
Risks
- Revenue stagnation at 1.4B with 0% YoY growth signals market saturation or competitive pressure in electromedical apparatus segment
- Severe net income decline of -64.5% YoY and sharp drop in diluted EPS to $1.51 indicate operational challenges or non-recurring charges requiring clarification
- Deteriorating net margin of 3.4% reflects compressed profitability despite stable gross margins, suggesting rising operating expenses or tax burden
- Low ROE of 4.6% and ROA of 2.0% indicate inefficient capital deployment relative to equity and asset base
- Minimal cash position of $40.8M relative to $1.3B liabilities limits financial flexibility for strategic investments or downturns
Key Metrics to Watch
- Revenue growth acceleration - must demonstrate organic growth resumption to validate market demand
- Net income trajectory - critical to understand whether -64.5% decline is temporary or structural
- Operating margin stability - monitor if 7.5% margin holds or continues compressing
- Free cash flow sustainability - validate that $150.9M FCF can be maintained with current capital efficiency
- Debt reduction progress - track deleveraging toward lower debt-to-equity given low profitability
Financial Metrics
Revenue
1.4B
Net Income
47.1M
EPS (Diluted)
$1.51
Free Cash Flow
150.9M
Total Assets
2.3B
Cash
40.8M
Profitability Ratios
Gross Margin
54.6%
Operating Margin
7.5%
Net Margin
3.4%
ROE
4.6%
ROA
2.0%
FCF Margin
11.0%
Balance Sheet & Liquidity
Current Ratio
2.14x
Quick Ratio
1.01x
Debt/Equity
0.81x
Debt/Assets
55.6%
Interest Coverage
3.30x
Long-term Debt
834.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T16:10:11.673140 |
Data as of: 2025-12-31 |
Powered by Claude AI